21 September 2018
Visiongain has launched a new pharma report: Global Acute Myeloid Leukaemia Market Forecast 2018-2028: Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults and among the most lethal. In the United States, the annual incidence of AML is 19 000 new cases, and the incidence of AML-associated deaths is 10 000.
The rapid increase in geriatric population is one of the major drivers for the acute myeloid leukaemia market. With age, patients become highly susceptible to diseases due to decreased immunity and degeneration. As per an article published by NCBI, Acute myeloid leukaemia (AML) is the common form of acute leukaemia in adults, accounting for over 80% of all acute leukaemia in those over the age of 18 years.
The lead analyst of the report commented "The growth of the acute myeloid leukaemia market is estimated to be catalysed by opportunities in emerging markets due to improving healthcare infrastructure, unmet healthcare needs, rise in chronic diseases, and increased awareness of treatment methods.
There is a need for better therapeutics and treatment options. The increasing incidence and lack of better treatment options pose a lucrative opportunity for the market to grow and expand."
Leading companies featured in the report include Bristol-Myers Squibb Company, Celgene, Clavis Pharma ASA, Daiichi Sankyo, Eisai, GSK, Novartis, Roche, Sunesis Pharmaceuticals, Teva
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.
05 July 2019
Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.
28 June 2019
Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.
25 June 2019
Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.